Lin, C-C
Su, W-C
Yen, C-J
Hsu, C-H
Su, W-P
Yeh, K-H
Lu, Y-S
Cheng, A-L
Huang, D C-L
Fritsch, H
Voss, F
Taube, T
Yang, J C-H
Article History
Received: 27 November 2013
Revised: 4 March 2014
Accepted: 17 March 2014
First Online: 22 April 2014
Competing interests
: A-LC: Honoraria from speakers bureau, Bayer Taiwan Co., Ltd, and consultant/advisory board Eisai Inc. and Excelixis Inc. DC-LH, HF, FV, and TT: employment, Boehringer Ingelheim. JC-HY: provided uncompensated expert testimony to afatinib produced by Boehringer Ingelheim in Taiwan FDA. The remaining authors declare no conflict of interest.